NCT01810666

Brief Summary

Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe Hemophilia A.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Mar 2013

Shorter than P25 for phase_4

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

March 12, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 13, 2013

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
1 year until next milestone

Results Posted

Study results publicly available

January 5, 2015

Completed
Last Updated

May 19, 2015

Status Verified

April 1, 2015

Enrollment Period

10 months

First QC Date

March 12, 2013

Results QC Date

December 22, 2014

Last Update Submit

April 30, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Difference of Annualized Number of All Bleeds Between On-demand and Prophylaxis Period

    Annualized bleedings period 1 minus period 2 ITT analysis set.

    Week 1-12 (on-demand treatment) and 13-24 (prophylactic treatment)

Secondary Outcomes (2)

  • Difference of Annualized Number of Joint Bleeds Between On-demand and Prophylaxis Period

    Week 1-12 (on-demand treatment) and 13-24 (prophylactic treatment)

  • Difference of Intra-individual Change of Joint Function During Each Period Assessed by the Hemophilia Joint Health Score Between On-demand and Prophylaxis Period

    From baseline to Week 12 (on-demand treatment) and Week 24 (prophylactic treatment)

Study Arms (1)

Recombinant Factor VIII

EXPERIMENTAL
Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Interventions

Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.

Recombinant Factor VIII

Eligibility Criteria

Age2 Years - 16 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Male, aged 2-16yrs
  • Severe hemophilia A (\<1% FVIII:C \[Blood Clotting Factor VIII:C\] )
  • Minimum of at least 50 documented ED (exposure day) prior to enrolment
  • No measurable inhibitor activity at baseline and history of FVIII inhibitor antibody formation
  • Parents or legal guardians document, sign, and date informed consent

You may not qualify if:

  • Another bleeding disease that is different from hemophilia A
  • Known hypersensitivity to the active substance, mouse or hamster protein
  • Thrombocytopenia (platelet count \<100 000/mm3) based on previous medical records

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Unknown Facility

Guangzhou, Guangdong, 510515, China

Location

Unknown Facility

Wuhan, Hubei, 430022, China

Location

Unknown Facility

Beijing, 100730, China

Location

Unknown Facility

Beijing, China

Location

Unknown Facility

Tianjin, China

Location

Related Links

MeSH Terms

Conditions

Hemophilia A

Interventions

Factor VIIIF8 protein, humanBAY 14-2222

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, InheritedBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesCoagulation Protein DisordersHemorrhagic DisordersGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Blood Coagulation FactorsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsProtein PrecursorsBiological Factors

Results Point of Contact

Title
Therapeutic Area Head
Organization
BAYER

Study Officials

  • Bayer Study Director

    Bayer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2013

First Posted

March 13, 2013

Study Start

March 1, 2013

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

May 19, 2015

Results First Posted

January 5, 2015

Record last verified: 2015-04

Locations